Lantern Pharma Stock Current Ratio
| LTRN Stock | USD 3.21 0.10 3.22% |
Lantern Pharma fundamentals help investors to digest information that contributes to Lantern Pharma's financial success or failures. It also enables traders to predict the movement of Lantern Stock. The fundamental analysis module provides a way to measure Lantern Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lantern Pharma stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 16.18 | 14.43 |
Lantern | Current Ratio |
Lantern Pharma Company Current Ratio Analysis
Lantern Pharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Lantern Pharma Current Ratio | 12.38 X |
Most of Lantern Pharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lantern Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lantern Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Lantern Pharma is extremely important. It helps to project a fair market value of Lantern Stock properly, considering its historical fundamentals such as Current Ratio. Since Lantern Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lantern Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lantern Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Lantern Current Ratio Historical Pattern
Today, most investors in Lantern Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lantern Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lantern Pharma current ratio as a starting point in their analysis.
Lantern Pharma Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Lantern Pharma has a Current Ratio of 12.38 times. This is 325.43% higher than that of the Biotechnology sector and 76.86% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Lantern Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lantern Pharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lantern Pharma could also be used in its relative valuation, which is a method of valuing Lantern Pharma by comparing valuation metrics of similar companies.Lantern Pharma is currently under evaluation in current ratio category among its peers.
Lantern Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lantern Pharma from analyzing Lantern Pharma's financial statements. These drivers represent accounts that assess Lantern Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lantern Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 93.7M | 119.8M | 87.0M | 65.5M | 46.4M | 92.6M | |
| Enterprise Value | 92.4M | 100.6M | 35.7M | 28.4M | 24.7M | 23.5M |
Lantern Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lantern Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lantern Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Lantern Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 6.86 M | ||||
| Shares Outstanding | 10.78 M | ||||
| Shares Owned By Insiders | 14.74 % | ||||
| Shares Owned By Institutions | 24.10 % | ||||
| Number Of Shares Shorted | 160.85 K | ||||
| Price To Book | 1.30 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.96 M) | ||||
| Cash And Equivalents | 62.15 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 234.47 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.38 X | ||||
| Book Value Per Share | 3.82 X | ||||
| Cash Flow From Operations | (14.35 M) | ||||
| Short Ratio | 4.74 X | ||||
| Earnings Per Share | (1.78) X | ||||
| Target Price | 20.5 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.57 | ||||
| Market Capitalization | 34.62 M | ||||
| Total Asset | 43.65 M | ||||
| Retained Earnings | (55.24 M) | ||||
| Working Capital | 40.66 M | ||||
| Net Asset | 43.65 M |
About Lantern Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lantern Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lantern Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lantern Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lantern Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lantern Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lantern Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Lantern Stock
Moving against Lantern Stock
| 0.71 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.7 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.53 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.53 | GILD | Gilead Sciences | PairCorr |
| 0.46 | EBS | Emergent Biosolutions | PairCorr |
The ability to find closely correlated positions to Lantern Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lantern Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lantern Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lantern Pharma to buy it.
The correlation of Lantern Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lantern Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Lantern Pharma Piotroski F Score and Lantern Pharma Altman Z Score analysis. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.